Brief: FDA Approves GSK's Jemperli As First Immunotherapy For MSI-H/DMMR Rectal Cancer
Mon 17:27
BRIEF-FDA Approves GSK's Jemperli As First Immunotherapy For MSI-H/DMMR Rectal Cancer Oct 19 (Reuters) - GSK plc GSK.L:
GSK PLC - JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER
GSK - NO DISEASE RECURRENCES REPORTED AMONG RESPONDERS AFTER TWO-YEAR MEDIAN FOLLOW UP
GSK - FDA APPROVES JEMPERLI AS FIRST IMMUNOTHERAPY FOR MSI-H/DMMR LOCALLY ADVANCED RECTAL CANCER
Source text: ID:nRSS5703Za
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))